News

Neuron-Optimised CRISPR Can Manipulate Neuron Gene Expression for First Time

26 February 2019

A neuron-optimised CRISPR-Cas9 activation system has been used by scientists to regulate genes in a rat brain for the first time. This technique could lead to researchers being able to probe genetic influences on brain health and disease in model organisms which more closely resemble humans.

25 February 2019

New “Hit and Run” CRISPR Delivery System Improves Efficiency

Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.

18 February 2019

Drug Combination Shows Survival Promise for Kidney Cancer Patients

A combination of immunotherapy drug avelumab and targeted agent axitinib has been seen to increases progression-free survival in patients with metastatic kidney cancer, scientists from the Dana-Farber Institute have reported following a phase 3 clinical trial.

18 February 2019

Bio-Rad’s PCR-Based Test for CML Finds FDA Approval

Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.

14 February 2019

Older Sperm Breeds Healthier Offspring

Sperm which lives longer before fertilising an egg produces more health children, Uppsala University and University of East Anglia (UEA) scientists have found.

14 February 2019

Oxbridge S&T Sector will Need “40 Football Fields” More Space Post-Brexit

The leading advisor for the UK science and technology (S&T) sectors has estimated that despite Brexit, Cambridge and Oxford’s S&T companies will require 2.5 million more square feet of lab and research space over the next five years, and are looking to accommodate 20,000 new R&D workers by 2023.

12 February 2019

“Trojan Horse” Antibody to Treat Cancers Reaches New Test Stage

Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.

8 February 2019

J&J is First Pharma Giant to Advertise Drug Prices on TV

Johnson and Johnson has vowed to become the first pharmaceutical giant to add its medicine prices to television adverts, starting in March 2018. The company said it will list not only product price before rebates or discounts, as well as potential out-of-pocket costs which patients will pay.